Search

Your search keyword '"Yuan, Chenglu"' showing total 30 results
Start Over Author "Yuan, Chenglu"
30 results on '"Yuan, Chenglu"'

9. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma

Author

An, Gang, Yan, Yuting, Xu, Yan, Mao, Xuehan, Liu, Jiahui, Fan, Huishou, Wang, Qi, Du, Chenxing, Li, Zengjun, Yi, Shuhua, Lv, Rui, Deng, Shuhui, Sui, Weiwei, Fu, Mingwei, Hao, Mu, Huang, Wenyang, Zou, Dehui, Zhao, Yaozhong, Yuan, Chenglu, Du, Xin, Wang, Jianxiang, Cheng, Tao, Tai, Yu-Tzu, Munshi, Nikhil C., and Qiu, Lugui

Published
2020
Full Text
View/download PDF

11. MM-028 Treatment Efficacy for Relapsed and Refractory Multiple Myeloma Patients With Gain or Amplification of 1q21: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Author

Zhou, Xia, primary, Hao, Hongyuan, additional, Wu, Hongying, additional, Hao, Lumei, additional, Wei, Liyan, additional, Li, Xuemei, additional, Yin, Junjing, additional, Yu, Qianru, additional, Xie, Zhanzhi, additional, Yuan, Chenglu, additional, and Zhong, Yuping, additional

Published
2023
Full Text
View/download PDF

12. POSTER: MM-028 Treatment Efficacy for Relapsed and Refractory Multiple Myeloma Patients With Gain or Amplification of 1q21: A Systematic Review and Meta- Analysis of Randomised Controlled Trials

Author

Zhou, Xia, primary, Hao, Hongyuan, additional, Wu, Hongying, additional, Hao, Lumei, additional, Wei, Liyan, additional, Li, Xuemei, additional, Yin, Junjing, additional, Yu, Qianru, additional, Xie, Zhanzhi, additional, Yuan, Chenglu, additional, and Zhong, Yuping, additional

Published
2023
Full Text
View/download PDF

16. The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Author

Fan, Huishou, primary, Liu, Jiahui, additional, Yuan, Chenglu, additional, Mao, Xue-Han, additional, LI, Xiaoqing, additional, Du, Xin, additional, Li, Zengjun, additional, Hao, Mu, additional, Yan, Yuting, additional, Deng, Shuhui, additional, Du, Chenxing, additional, Li, Chengwen, additional, Zhao, Jiawei, additional, Yi, Shuhua, additional, Zou, Dehui, additional, Zhao, Yaozhong, additional, Zhan, Fenghuang, additional, Tai, Yu-Tzu, additional, Wang, Jianxiang, additional, Anderson, Kenneth, additional, Qiu, Lugui, additional, and An, Gang, additional

Published
2020
Full Text
View/download PDF

17. High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial

Author

Yu, Yafei, primary, Wang, Miaomiao, additional, Hou, Yu, additional, Qin, Ping, additional, Zeng, Qingshu, additional, Yu, Wenzheng, additional, Guo, Xinhong, additional, Wang, Jingxia, additional, Wang, Xiaomin, additional, Liu, Guoqiang, additional, Chu, Xiaoxia, additional, Yang, Lan, additional, Feng, Ying, additional, Zhou, Fang, additional, Sun, Zhaogang, additional, Zhang, Mei, additional, Wang, Xin, additional, Wang, Zhencheng, additional, Ran, Xuehong, additional, Zhao, Hongguo, additional, Wang, Lei, additional, Zhang, Haiyan, additional, Bi, Kehong, additional, Li, Daqi, additional, Yuan, Chenglu, additional, Xu, Ruirong, additional, Wang, Yili, additional, Zhou, Yuhong, additional, Peng, Jun, additional, Liu, Xin‐guang, additional, and Hou, Ming, additional

Published
2020
Full Text
View/download PDF

19. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib

Author

Du, Chenxing, primary, Mao, Xuehan, additional, Xu, Yan, additional, Yan, Yuting, additional, Yuan, Chenglu, additional, Du, Xin, additional, Liu, Jiahui, additional, Fan, Huishou, additional, Wang, Qi, additional, Sui, Weiwei, additional, Deng, Shuhui, additional, Fu, Mingwei, additional, Li, Zengjun, additional, Li, Chengwen, additional, Zhao, Jiawei, additional, Yi, Shuhua, additional, Liu, Lanting, additional, Hao, Mu, additional, Zou, Dehui, additional, Zhao, Yaozhong, additional, Qiu, Lugui, additional, and An, Gang, additional

Published
2019
Full Text
View/download PDF

20. Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Author

Yao, Yuan, primary, Zou, Dehui, additional, Liao, Aijun, additional, Chu, Xiaoxia, additional, Wang, Wei, additional, Cen, Xinan, additional, Chen, Lijuan, additional, Bao, Li, additional, Fu, Rong, additional, Liu, Hui, additional, Sun, Chunyan, additional, Wang, Luqun, additional, Jin, Fengyan, additional, Yan, Hua, additional, Yuan, Chenglu, additional, Ma, Liangming, additional, Gao, Guangxun, additional, Zhang, Jinqiao, additional, Gao, Da, additional, Hu, Jianda, additional, He, Jianxia, additional, Zhao, Ai-lin, additional, Zhang, Lu, additional, Zhou, Dao-Bin, additional, and Li, Jian, additional

Published
2019
Full Text
View/download PDF

22. A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia

Author

Zhou, Hai, primary, Qin, Ping, additional, Liu, Qiang, additional, Yuan, Chenglu, additional, Hao, Yunliang, additional, Zhang, Haiyan, additional, Wang, Zhencheng, additional, Ran, Xuehong, additional, Chu, Xiaoxia, additional, Yu, Wenzheng, additional, Wang, Xin, additional, Hou, Yu, additional, Peng, Jun, additional, and Hou, Ming, additional

Published
2019
Full Text
View/download PDF

23. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma

Author

An, Gang, primary, Yan, Yuting, additional, Xu, Yan, additional, Mao, Xuehan, additional, Liu, Jiahui, additional, Fan, Huishou, additional, Wang, Qi, additional, Du, Chenxing, additional, Li, Zengjun, additional, Yi, Shuhua, additional, Lv, Rui, additional, Deng, Shuhui, additional, Sui, Weiwei, additional, Fu, Mingwei, additional, Hao, Mu, additional, Huang, Wenyang, additional, Zou, Dehui, additional, Zhao, Yaozhong, additional, Yuan, Chenglu, additional, Du, Xin, additional, Wang, Jianxiang, additional, Cheng, Tao, additional, Tai, Yu-Tzu, additional, Munshi, Nikhil C., additional, and Qiu, Lugui, additional

Published
2019
Full Text
View/download PDF

24. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.

Author

Du, Chenxing, Mao, Xuehan, Xu, Yan, Yan, Yuting, Yuan, Chenglu, Du, Xin, Liu, Jiahui, Fan, Huishou, Wang, Qi, Sui, Weiwei, Deng, Shuhui, Fu, Mingwei, Li, Zengjun, Li, Chengwen, Zhao, Jiawei, Yi, Shuhua, Liu, Lanting, Hao, Mu, Zou, Dehui, and Zhao, Yaozhong

Subjects
MULTIPLE myeloma, CHROMOSOME abnormalities, KARYOTYPES, BORTEZOMIB
Abstract

Chromosome 1q21 aberrations in multiple myeloma have attracted much attention for a long time, however, the prognostic value is still under investigation. We confirmed the independent prognostic impact of 1q21 aberrations in this non-randomized clinical study. Our study noted that additional copies and larger clonal size of 1q21 gain did not worsen the outcome. We discovered that 1q21 gain was associated with the acquisition of new chromosome abnormalities and genomic instability, evidenced by the strong correlation between 1q21 gain and complex karyotypes or the acquisition of more than two cytogenetic aberrations. Moreover, 1q21 gain and/or del(17p) were powerful enough to discriminate high-risk patients. Furthermore, 1q21 gain retained unfavorable even when stratified by concurrent presence of t(4;14), especially in the bortezomib arm. Finally, although bortezomib might benefit patients with 1q21 gain, it could not completely overcome its adverse effects, suggesting the necessity of more effective therapies for these patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

26. Selinexor Combined Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma with Extramedullary Disease(EMD) or High-Risk Cytogenetics

Author

Zhong, Yuping, Chu, Xiaoxia, Xu, Junqing, Liu, Xiaoqian, Yuan, Chenglu, Zhou, Xia, Wu, Hongying, Wang, Yayun, Yu, Shuyuan, Zhang, Hongyan, and Mei, Jay

Abstract

BACKGROUND:High-risk(HR) cytogenetics are significantly enriched in MM with EMD , and studies consistently showed EMD and HR cytogenetics were associated with poor outcome. To date, there is no established approach for treatment of newly diagnosed multiple myeloma (NDMM) with EMD. Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that selectively binds and inactivates XPO1, which leads to accumulation of tumor suppressor proteins in the nucleus and re-activation of cell cycle regulators such as p53, FOXO, IkB. Meanwhile, by forcing the nuclear retention of the eIF4E protein, Selinexor reduces the cytoplasmic ribosomal translation of oncoproteins, including c-Myc, Bcl-2 and Bcl-6. In the STORM study(NCT02343042), 122 patients(pts) with penta-exposed, triple-class refractory multiple myeloma were enrolled to receive Selinexor combined with low-dose dexamethasone. 27 patients were diagnosed with EMD at baseline. The median age of patients was 64 years, the median prior therapies were 7, and 8 pts had high risk cytogenetics. Follow-up evaluation of plasma cell tumor was performed in 16 cases, and complete disappearance or shrinkage of extramedullary lesions was observed in 9 cases. It indicates that Selinexor has clinical activity in the treatment of plasma cell tumor or EMD. The treatment of MM with EMD or HR cytogenetics still faces great challenges, because there is no uniform guideline and consensus to recommend standard protocols, and prospective clinical studies are urgently needed to explore new treatment strategies.

Published
2023
Full Text
View/download PDF

28. Recombinant Human Thrombopoietin (rhTPO) and High-Dose Dexamethasone (HD-DXM) Versus High-Dose Dexamethasone Monotherapy As Frontline Treatment in Newly Diagnosed Adult Immune Thrombocytopenia (ITP): a Prospective, Multicentre, Randomised, Controlled Trial

Author

Wang, Miaomiao, Qin, Ping, Zhou, Hai, Zhou, Fang, Zhao, Hongguo, Wang, Xin, Xu, Ruirong, Li, Daqi, Wang, Lei, Zhou, Yuhong, Feng, Ying, Zhang, Mei, Yang, Lan, Wang, Xiaomin, Zeng, Qingshu, Zhang, Haiyan, Sun, Zhaogang, Wang, Jingxia, Liu, Guoqiang, Guo, Xinhong, Wang, Zhencheng, Yu, Wenzheng, Chu, Xiaoxia, Yuan, Chenglu, Bi, Kehong, Wang, Yili, Ran, Xuehong, Peng, Jun, and Hou, Ming

Published
2017
Full Text
View/download PDF

30. Recombinant Human Thrombopoietin and Rituximab vs Rituximab Monotherapy in Corticosteroid-Resistant Primary Immune Thrombocytopenia: a Multicenter Randomized Controlled Study

Author

Xu, Miao, primary, Qin, Ping, additional, Dong, Xiaoyuan, additional, Li, Jie, additional, Zhang, Haiyan, additional, Wang, Xin, additional, Meng, Yuesheng, additional, Yuan, Chenglu, additional, Zhao, Hongguo, additional, Peng, Jun, additional, and Hou, Ming, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results